外源性性激素及性激素受体调节剂用于COVID-19的合理性与临床药理学考量
多项研究数据显示男性COVID-19患者在疾病严重程度和死亡率方面均较女性患者更差。基于这一性别差异,研究者提出外源性性激素治疗及性激素受体调节剂可能为COVID-19患者提供治疗潜力。本文综述了外源性性激素及性激素受体调节剂用于COVID-19治疗的理论依据,总结了正在进行和计划中的临床试验,并讨论了临床研究设计中的临床药理学考量。
要点
- 男性COVID-19患者在严重程度和死亡率方面较女性患者更差。
- 外源性性激素及性激素受体调节剂可能为COVID-19提供治疗潜力。
- 临床研究设计需关注给药方案、特殊人群和药物相互作用等临床药理学因素。
核心结论
- 外源性性激素及性激素受体调节剂基于性别差异假说具有COVID-19治疗潜力,但需在临床研究中充分考虑临床药理学因素。
研究设计与样本
- 本文为综述,讨论外源性性激素及性激素受体调节剂用于COVID-19治疗的理论依据,总结正在进行和计划中的临床试验,并讨论临床研究设计中的临床药理学考量。
主要发现
- 多项研究数据显示男性COVID-19患者在疾病严重程度和死亡率方面较女性患者更差。
- 已获批药物或处于晚期临床开发阶段的候选药物因临床制剂、给药途径、给药方案、临床药理学和潜在不良事件已在人体中确立或表征,可加速COVID-19治疗开发。
- 多种外源性性激素及性激素受体调节剂目前正在或将要进行COVID-19治疗的临床研究。
临床怎么用
- 临床研究者在设计外源性性激素及性激素受体调节剂用于COVID-19治疗的临床试验时,应关注给药方案、特殊人群(老年、妊娠、哺乳、肾/肝损伤)和药物相互作用等临床药理学因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Male patients with coronavirus disease 2019 (COVID-19) fare much worse than female patients in COVID-19 severity and mortality according to data from several studies. Because of this sex disparity, researchers hypothesize that the use of exogenous sex hormone therapy and sex hormone receptor modulators might provide therapeutic potential for patients with COVID-19. Repurposing approved drugs or drug candidates at late-stage clinical development could expedite COVID-19 therapy development because their clinical formulation, routes of administration, dosing regimen, clinical pharmacology, and potential adverse events have already been established or characterized in humans. A number of exogenous sex hormones and sex hormone receptor modulators are currently or will be under clinical investigation for COVID-19 therapy. In this review, we discuss the rationale for exogenous sex hormones and sex hormone receptor modulators in COVID-19 treatment, summarize ongoing and planned clinical trials, and discuss some of the clinical pharmacology considerations on clinical study design. To inform clinical study design and facilitate the clinical development of exogenous sex hormones and sex hormone receptor modulators for COVID-19 therapy, clinical investigators should pay attention to clinical pharmacology factors, such as dosing regimen, special populations (i.e., geriatrics, pregnancy, lactation, and renal/hepatic impairment), and drug interactions.
引用
- Zou P, Heath A, Sewell C, et al. EXOGENOUS Sex Hormones and Sex Hormone Receptor Modulators in COVID-19: Rationale and Clinical Pharmacology Considerations. Clin Pharmacol Ther. 2021. PMID: 34888850. doi:10.1002/cpt.2508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。